Skip to main content

Benitec Biopharma Inc. (BNTC)

NASDAQ: BNTC · Delayed Price · USD
2.99
0.01 (0.34%)
At close: Dec 8, 2021 4:00 PM
3.02
0.03 (1.00%)
After-hours:Dec 8, 2021 4:00 PM EST
Market Cap24.43M
Revenue (ttm)4,000
Net Income (ttm)-16.21M
Shares Out8.17M
EPS (ttm)-2.67
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume39,352
Open2.85
Previous Close2.98
Day's Range2.85 - 3.19
52-Week Range2.30 - 10.49
Beta1.64
Analystsn/a
Price Targetn/a
Earnings DateNov 12, 2021

About BNTC

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

IndustryBiotechnology
Founded1995
Employees14
Stock ExchangeNASDAQ
Ticker SymbolBNTC
Full Company Profile

Financial Performance

Financial numbers in millions AUDFinancial Statements

News

Benitec Biopharma Discloses Q1 2022 Financial Results

HAYWARD, Calif., Nov. 15, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel genet...

3 weeks ago - PRNewsWire

Benitec Biopharma Provides Operational Update and Releases its 2021 Fiscal Year-End Financial Results

HAYWARD, Calif., Sept. 20, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel gene...

2 months ago - PRNewsWire

Benitec Biopharma to present at H.C. Wainwright's 23rd Annual Global Investment Conference

HAYWARD, Calif., Sept. 13, 2021 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the p...

2 months ago - PRNewsWire

Benitec Biopharma Provides Overview of the BB-301 Phase 1b/2a Clinical Trial Design for 2022

HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an o...

3 months ago - PRNewsWire

Benitec Biopharma Provides Positive Updates on the BB-301 Pilot Dosing Study in Large Animals

HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC), a development-stage biotechnology company focused on the advancement of novel genetic medicines, today provided an u...

3 months ago - PRNewsWire

Benitec Biopharma Provides Positive Regulatory Updates for the BB-301 Development Program; BB-301 Phase 1b/2a Clinica...

HAYWARD, Calif., Sept. 8, 2021 /PRNewswire/ -- Regulatory Update Highlights: Regarding European Regulatory Interactions: The BB-301 Pilot Dosing Study was viewed as an appropriate dose range finding stu...

3 months ago - PRNewsWire

Benitec Biopharma Increases Previously Announced Bought Deal Offering of Common Stock to $12.9 Million

HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel gene...

7 months ago - PRNewsWire

Benitec Biopharma Announces $7.5 Million Bought Deal Offering of Common Stock

HAYWARD, Calif., April 27, 2021 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel gene...

7 months ago - PRNewsWire

Benitec BioPharma Shares Rally: Technical Levels To Watch

Benitec BioPharma Inc. (NASDAQ: BNTC) shares rallied Tuesday following a filing by Morgan Stanley that showed the bank increased its stake in the Australian biotechnology company by 5.2%. The stock gain...

8 months ago - Benzinga

Why DLPN Stock And BNTC Stock Are Popping Off Today

Dolphin Entertainment Inc (NASDAQ: DLPN) shares are trading 150% higher after the company announced it launched a non-fungible token (NFT) creation and marketing division. Dolphin Entertainment produces...

Other symbols:DLPN
8 months ago - Benzinga

BNTC Stock: One Big Investor Has Benitec Biopharma Shares Going Bonkers

Benitec Biopharma (BNTC) stock is rocketing higher in early morning trading on Tuesday after disclosing a new large stake in the company. The post BNTC Stock: One Big Investor Has Benitec Biopharma Shar...

8 months ago - InvestorPlace

Why Benitec Biopharma (BNTC) Stock Is Skyrocketing Today

The shares of Benitec Biopharma Inc (NASDAQ: BNTC) are trading 92.5% higher at $6.14 in the early pre-market session on Tuesday.  What Happened: Benitec shares had closed at $3.19 on Monday.

8 months ago - Benzinga

Benitec Biopharma's Gene Therapy For Rare Muscle Disorder Shows Encouraging Action In Animal Studies

Benitec Biopharma Inc (NASDAQ: BNTC) reports an interim analysis of the BB-301 Pilot Dosing study conducted in large animal subjects. BB-301 a genetic medicine directly injected into the pharyngeal musc...

9 months ago - Benzinga

Benitec Biopharma Announces 2020 Annual Stockholder Meeting

HAYWARD, Calif., Dec. 7, 2020 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), today announced that its 2020 Annual Meeting of Stockholders will be held virtually on Wednesday December 9, 2020 at...

1 year ago - PRNewsWire

Benitec Biopharma Announces Closing of $11.5 Million Public Offering and Full Exercise of Underwriter's Option to Pur...

HAYWARD, Calif., Oct. 6, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel geneti...

1 year ago - PRNewsWire

Benitec Biopharma Announces Pricing of $10.0 Million Public Offering

HAYWARD, Calif., Oct. 2, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel geneti...

1 year ago - PRNewsWire

Benitec Biopharma Provides Operational Update and Releases its 2020 Fiscal Year-End Financial Results

HAYWARD, Calif., Sept. 23, 2020 /PRNewswire/ -- Benitec Biopharma Inc. (NASDAQ: BNTC) ("Benitec" or "the Company"), a development-stage, gene therapy-focused, biotechnology company developing novel gene...

1 year ago - PRNewsWire

Benitec Biopharma to present at H.C. Wainwright's 22nd Annual Global Investment Conference

HAYWARD, Calif., Sept. 1, 2020 /PRNewswire/ -- Benitec Biopharma, Inc.

1 year ago - PRNewsWire

Benitec Biopharma Provides Update on BB-301 Tissue Transduction Study

HAYWARD, Calif., July 8, 2020 /PRNewswire/ -- Benitec Biopharma, Inc. (NASDAQ: BNTC), a development-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on the pro...

1 year ago - PRNewsWire

Penny Stocks to Buy Using Technical Analysis for March 2020

Penny stocks can be dangerous, particularly in this economic environment – so quick thinking and stop losses will be your best friends.

Other symbols:SUPVTRIB
1 year ago - Investopedia